Immunocore Holdings Plc (IMCR)
NASDAQ:IMCR
Want to see IMCR full AI Analyst Report?
IMCR Stock Chart & Stats
$31.45
-$0.07(-0.21%)
At close: 4:00 PM EST
$31.45
-$0.07(-0.21%)
Day’s Range― - ―
52-Week Range$27.56 - $40.71
Previous CloseN/A
Volume28.13K
Average Volume (3M)394.33K
Market Cap
$1.48B
Enterprise Value$1.43B
Total Cash (Recent Filing)$844.90M
Total Debt (Recent Filing)$435.68M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 06, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding50,865,574
10 Day Avg. Volume405,035
30 Day Avg. Volume394,330
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)4.59
Price to Sales (P/S)5.87
P/FCF Ratio-156.07
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue3.72
Enterprise Value/Gross Profit3.76
Enterprise Value/Ebitda229.83
Forecast
1Y Price Target
$69.71Price Target Upside121.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$447.95M
Bulls Say, Bears Say
Bulls Say
Commercial Product + PlatformHaving an approved, revenue-generating therapy (KIMMTRAK) plus a proprietary ImmTAX TCR platform provides durable structural advantages: an established commercial engine to fund operations and a scalable R&D platform that can generate multiple pipeline assets and long-term revenue diversification.
Revenue Scaling And Gross ProfitabilityMaterial revenue growth alongside consistently very high gross margins indicates strong unit economics and pricing power in core products. This supports sustained reinvestment into R&D and commercialization, improving chances of durable profitability as operating leverage continues to improve.
Conservative Leverage / Balance Sheet CushionA low-leverage balance sheet provides financial flexibility to fund trials, commercial rollouts, and strategic partnerships without immediate refinancing pressure. This cushion reduces near-term solvency risk and preserves optionality for capital allocation or opportunistic M&A.
Bears Say
Negative Operating/free Cash FlowSustained negative operating and free cash flow indicate ongoing cash burn from R&D and commercialization. This elevates reliance on external financing or partnerships, increases dilution and execution risk, and limits the company's ability to self-fund growth until cash flow turns reliably positive.
Ongoing Net LossesContinued negative EBIT and net income mean operating leverage is not yet durable. Profitability remains sensitive to market uptake, pricing and reimbursement trends; until sustained positive operating profit is achieved, returns on capital and equity will likely stay negative.
Historical Leverage VolatilityPast swings to materially higher debt demonstrate capital-structure sensitivity to funding needs. If market conditions tighten or cash burn persists, the company could face refinancing risk or higher borrowing costs, which would weaken financial resilience despite current low leverage.
Immunocore Holdings News
IMCR FAQ
What was Immunocore Holdings Plc’s price range in the past 12 months?
Immunocore Holdings Plc lowest stock price was $27.55 and its highest was $40.71 in the past 12 months.
What is Immunocore Holdings Plc’s market cap?
Immunocore Holdings Plc’s market cap is $1.48B.
When is Immunocore Holdings Plc’s upcoming earnings report date?
Immunocore Holdings Plc’s upcoming earnings report date is Aug 06, 2026 which is in 42 days.
How were Immunocore Holdings Plc’s earnings last quarter?
Immunocore Holdings Plc released its earnings results on May 06, 2026. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of -$0.237 by $0.487.
Is Immunocore Holdings Plc overvalued?
According to Wall Street analysts Immunocore Holdings Plc’s price is currently Undervalued.
Does Immunocore Holdings Plc pay dividends?
Immunocore Holdings Plc does not currently pay dividends.
What is Immunocore Holdings Plc’s EPS estimate?
Immunocore Holdings Plc’s EPS estimate is 0.01.
How many shares outstanding does Immunocore Holdings Plc have?
Immunocore Holdings Plc has 50,865,574 shares outstanding.
What happened to Immunocore Holdings Plc’s price movement after its last earnings report?
Immunocore Holdings Plc reported an EPS of $0.25 in its last earnings report, beating expectations of -$0.237. Following the earnings report the stock price went up 6.553%.
Which hedge fund is a major shareholder of Immunocore Holdings Plc?
Currently, no hedge funds are holding shares in IMCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunocore Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.71 (121.67% Upside)
$69.71 (121.67% Upside)
Blogger Sentiment
Bullish
IMCR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.16%
12-Months-Change
Fundamentals
Return on Equity
-4.83%
Trailing 12-Months
Asset Growth
4.29%
Trailing 12-Months
Company Description
Immunocore Holdings Plc
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
IMCR Stock 12 Month Forecast
Average Price Target
$69.71
▲(121.67% Upside)
Technical Analysis
Ownership Overview
0.04% Insiders
26.32% Mutual Funds
64.84% Other Institutional Investors
7.53% Public Companies and
Individual Investors